Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting Genetic Modifiers

 Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting Genetic Modifiers

Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting Genetic Modifiers

Shots:

  • Scenic to receive ~$375M that includes up front, milestones along with royalties on sales of therapies emerges from the collaboration and will receive additional target fees for the therapies selected by Genentech
  • The collaboration allows the Genentech to select multiple targets for further development with an option to extend the collaboration. Scenic will leverage its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas
  • Scenic’s data warehouse of genetic modifiers and its Cell-Seq platform enables the development of potential disease-modifying therapies for devastating diseases with an in-house focus on inherited rare diseases and immuno-oncology/inflammation

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Stat

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post